Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Durata Prices IPO Of 7.5 Mln Shares At $9.00/shr, Before Underwriting Discounts

Durata Therapeutics (DRTX: Quote) announced the pricing of its initial public offering of 7.5 million shares of common stock at a public offering price of $9.00 per share, before underwriting discounts.

The shares are scheduled to commence trading on the NASDAQ Global Market on July 19, 2012 under the ticker symbol "DRTX", noted the company.

Durata further stated that the underwriters have an option for a period of 30 days to buy up to an additional 1.13 million shares of common stock from the company at the public offering price, less the underwriting discount. The offering is expected to close on or about July 24, 2012.

Click here to receive FREE breaking news email alerts for Durata Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
With traders seemingly reluctant to make any significant moves, stocks are showing a lack of direction in early trading on Thursday. The major averages are lingering near the unchanged line after ending the previous session firmly in the red. First-time claims for U.S. unemployment benefits unexpectedly decreased in the week ended September 27th, according to a report released by the Labor Department on Thursday. The report said initial jobless claims fell to 287,000, a decrease of 8,000 from the previous week's revised level of 295,000. The European Central Bank left its key interest rates unchanged at a record low, after reducing them in a surprise move last month, as economic momentum in the euro area remains subdued. The Governing Council, led by President Mario Draghi, held the refinancing rate at a record low 0.05 percent following its policy meeting in Naples, Italy on Thursday.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.